Introduction. Nowadays obesity is one of the most significant problems of today health system. According to the data of the World Health Organization, the number of patients with excessive weight will be doubled by the year of 2025. This abnormality has strong correlation with the insulin resistance, metabolic syndrome, cardiovascular diseases, diabetes mellitus etc. One of the ways to treat obesity is the effect on the endocannabinoid system. The aim of this work was the study of therapeutic influence mechanisms by the affinity-purified antibodies to the endocannabinoid receptor CB-1 type on the model of experimental MS in Syrian Golden hamsters.
Materials and methods. In the experiment there were used the males of Syrian Golden hamsters modulated the experimental metabolic syndrome.
Results and discussion. Animals keeping on a high calorie diet had development of insulin resistance syndrome, the formation of atherogenic dyslipidemia and hyperuricemia. Hyperglycaemia and hyperinsulinemia occurred, index НОМА-IR increased 1.77 times. Concentration of FFA increased 3.42 times. Under this conditions the level of TAG and apoB-LP increased rapidly while HDL decreased significantly. This confirmed the formation of atherogenic dyslipidemia. Hyperuricemia was realized by several mechanisms: hyperinsulinemia led to increased urates reabsorption and reduced levels of adiponectin, which negatively correlated with the level of uric acid. Administration of developed medicine led to normalization of the above mentioned parameters. It was determined by normalization of eating behavior and the metabolic activity of adipose tissue. Hypouricemic effect probably caused by positively influence on adiponectine level by affecting the endocannabinoid system.